Boothbay Fund Management’s bluebird bio BLUE Stock Holding History

Boothbay Fund Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,621	Closed	-$238K	–	1747
2023 Q2	$238K	Hold	3,621	–	–	0.01%	1418
2023 Q1	$230K	Sell	3,621 -3,511	-49%	-$401K	﹤0.01%	1658
2022 Q4	$987K	Buy	7,132 +3,043	+74%	+$429K	0.02%	903
2022 Q3	$518K	Buy	+4,089	New	+$463K	0.01%	1209
2021 Q1	–	Sell	-402	Closed	-$198K	–	1547
2020 Q4	$226K	Buy	+402	New	+$255K	0.01%	1062
2020 Q3	–	Sell	-587	Closed	-$464K	–	1048
2020 Q2	$464K	Buy	+587	New	+$443K	0.03%	601
2019 Q1	–	Sell	-212	Closed	-$373K	–	754
2018 Q4	$273K	Buy	+212	New	+$325K	0.04%	407

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Boothbay Fund Management's BLUE Position: Q3 2023 in Review

Boothbay Fund Management sold out of bluebird bio (BLUE) in Q3 2023, closing a stake of 3,621 shares — an estimated $238K sold.

Boothbay Fund Management first reported a position in BLUE in Q4 2018 and held it in 7 quarters. The position peaked at $987K in Q4 2022. 168 funds tracked by Wall St. Rank hold BLUE as of Q3 2023.

Boothbay Fund Management reported no remaining bluebird bio position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 3,621 bluebird bio shares in Q3 2023, an estimated $238K.
Boothbay Fund Management first reported a position in bluebird bio in Q4 2018 and held it in 7 quarters.
Boothbay Fund Management's bluebird bio position peaked at $987K in Q4 2022.
168 funds tracked by Wall St. Rank held bluebird bio as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.